Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

J. Weber, M. Mandala, M. Del Vecchio, H.J. Gogas, A.M. Arance, C.L. Cowey, S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Marquez-Rodas, J.-J. Grob, M.O. Butler, M.R. Middleton, M. Maio, V. Atkinson, P. Queirolo, R. Gonzalez, R.R. Kudchadkar, M. Smylie, N. MeyerL. Mortier, M.B. Atkins, G.V. Long, S. Bhatia, C. Lebbé, P. Rutkowski, K. Yokota, N. Yamazaki, T.M. Kim, V. De Pril, J. Sabater, A. Qureshi, J. Larkin, P.A. Ascierto

Research output: Contribution to journalArticle

Original languageUndefined/Unknown
Pages (from-to)1824-1835
Number of pages12
JournalNew England Journal of Medicine
Volume377
Issue number19
DOIs
Publication statusPublished - 2017

Cite this

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., ... Ascierto, P. A. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New England Journal of Medicine, 377(19), 1824-1835. https://doi.org/10.1056/NEJMoa1709030